Rita S. Axelrod
Advanced in Olfactory Neuroblastoma

Dr. Rita S. Axelrod

Oncology
Jefferson Health
Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Advanced in Olfactory Neuroblastoma
Jefferson Health
Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Rita Axelrod is an Oncologist in Philadelphia, Pennsylvania. Dr. Axelrod is rated as an Advanced provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Head and Neck Squamous Cell Carcinoma (HNSCC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Lung Adenocarcinoma. Dr. Axelrod is currently accepting new patients.

Her clinical research consists of co-authoring 35 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
New York University School Of Medicine
Residency
St. Luke's-Roosevelt Hospital Center
Specialties
Oncology
Licenses
Internal Medicine in PA
Board Certifications
Medical Oncology
Internal Medicine
Hematology
Fellowships
Lankenau Hospital
Philadelphia General Hospital (now closed)
Hospital Affiliations
Thomas Jefferson University Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Jefferson Cancer - Honickman Center
1101 Chestnut Street, Floor 14, Philadelphia, PA 19107
Call: 215-955-8874

Additional Areas of Focus

Dr. Axelrod has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Esophageal Cancer
Craniopharyngioma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients With Borderline Performance Status
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 20, 2025
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Active_not_recruiting
Publish Date: July 11, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Radiation, Drug
Study Drug: MK-3475
Study Phase: Phase 1
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers
Enrollment Status: Completed
Publish Date: May 15, 2025
Intervention Type: Other
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Avelumab, Cetuximab
Study Phase: Phase 2
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Enrollment Status: Withdrawn
Publish Date: October 18, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug
Study Drugs: Avelumab, Talazoparib, Talazoparib Tosylate
Study Phase: Phase 2
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

35 Total Publications

Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial.
Neoadjuvant nivolumab plus carboplatin and paclitaxel in patients with locally advanced resectable squamous cell carcinoma of the head and neck: a phase II, single-arm trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 04, 2025
View All 35 Publications
Similar Doctors
Distinguished in Olfactory Neuroblastoma
Dr. Tara C. Mitchell
Oncology
Distinguished in Olfactory Neuroblastoma
Dr. Tara C. Mitchell
Oncology

Abramson Cancer Center Perelman 3rd Floor West

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (1.9 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tara Mitchell is an Oncologist in Philadelphia, Pennsylvania. Dr. Mitchell is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. Her top areas of expertise are Melanoma, Merkel Cell Carcinoma, Olfactory Neuroblastoma, and Teratocarcinosarcoma. Dr. Mitchell is currently accepting new patients.

Distinguished in Olfactory Neuroblastoma
Dr. Roger B. Cohen
Oncology
Distinguished in Olfactory Neuroblastoma
Dr. Roger B. Cohen
Oncology

Abramson Cancer Center Perelman 2nd Floor West

3400 Civic Center Boulevard, West Pavilion, 2nd Floor, 
Philadelphia, PA 
 (1.9 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Roger Cohen is an Oncologist in Philadelphia, Pennsylvania. Dr. Cohen is rated as an Elite provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Tissue Biopsy, and Endoscopy. Dr. Cohen is currently accepting new patients.

Anthony P. Scarpaci
Distinguished in Olfactory Neuroblastoma
Dr. Anthony P. Scarpaci
Oncology | Hematology
Distinguished in Olfactory Neuroblastoma
Dr. Anthony P. Scarpaci
Oncology | Hematology

Medical Oncology & Infusion Suite - 900 Medical Center Drive

900 Medical Center Drive, Suite 200, 
Sewell, NJ 
 (15.4 miles away)
856-557-7900
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Anthony Scarpaci is a Hematologist and an Oncologist in Sewell, New Jersey. Dr. Scarpaci is rated as a Distinguished provider by MediFind in the treatment of Olfactory Neuroblastoma. His top areas of expertise are Olfactory Neuroblastoma, Teratocarcinosarcoma, Sinus Cancer, and Paget Disease of the Breast. Dr. Scarpaci is currently accepting new patients.

VIEW MORE OLFACTORY NEUROBLASTOMA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Axelrod's expertise for a condition
ConditionClose
    • Distinguished
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Axelrod is
      Distinguished
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • EGFR Positive Lung Cancer
      Dr. Axelrod is
      Distinguished
      . Learn about EGFR Positive Lung Cancer.
      See more EGFR Positive Lung Cancer experts
    • Head and Neck Squamous Cell Carcinoma (HNSCC)
      Dr. Axelrod is
      Distinguished
      . Learn about Head and Neck Squamous Cell Carcinoma (HNSCC).
      See more Head and Neck Squamous Cell Carcinoma (HNSCC) experts
    • Large-Cell Lung Carcinoma
      Dr. Axelrod is
      Distinguished
      . Learn about Large-Cell Lung Carcinoma.
      See more Large-Cell Lung Carcinoma experts
    • Lung Adenocarcinoma
      Dr. Axelrod is
      Distinguished
      . Learn about Lung Adenocarcinoma.
      See more Lung Adenocarcinoma experts
    • Lung Cancer
      Dr. Axelrod is
      Distinguished
      . Learn about Lung Cancer.
      See more Lung Cancer experts
    View All 12 Distinguished Conditions
    • Advanced
    • Melanoma of the Eye
      Dr. Axelrod is
      Advanced
      . Learn about Melanoma of the Eye.
      See more Melanoma of the Eye experts
    • Metastatic Brain Tumor
      Dr. Axelrod is
      Advanced
      . Learn about Metastatic Brain Tumor.
      See more Metastatic Brain Tumor experts
    • Nasopharyngeal Carcinoma
      Dr. Axelrod is
      Advanced
      . Learn about Nasopharyngeal Carcinoma.
      See more Nasopharyngeal Carcinoma experts
    • Olfactory Neuroblastoma
      Dr. Axelrod is
      Advanced
      . Learn about Olfactory Neuroblastoma.
      See more Olfactory Neuroblastoma experts
    • Sinus Cancer
      Dr. Axelrod is
      Advanced
      . Learn about Sinus Cancer.
      See more Sinus Cancer experts
    • Teratocarcinosarcoma
      Dr. Axelrod is
      Advanced
      . Learn about Teratocarcinosarcoma.
      See more Teratocarcinosarcoma experts
    View All 7 Advanced Conditions
    • Experienced
    • Acinic Cell Carcinoma of Salivary Glands
      Dr. Axelrod is
      Experienced
      . Learn about Acinic Cell Carcinoma of Salivary Glands.
      See more Acinic Cell Carcinoma of Salivary Glands experts
    • Adenoid Cystic Carcinoma
      Dr. Axelrod is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Anaplastic Thyroid Cancer
      Dr. Axelrod is
      Experienced
      . Learn about Anaplastic Thyroid Cancer.
      See more Anaplastic Thyroid Cancer experts
    • Bone Tumor
      Dr. Axelrod is
      Experienced
      . Learn about Bone Tumor.
      See more Bone Tumor experts
    • Brain Stem Cancer
      Dr. Axelrod is
      Experienced
      . Learn about Brain Stem Cancer.
      See more Brain Stem Cancer experts
    • Breast Cancer
      Dr. Axelrod is
      Experienced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.